gptkbp:instanceOf
|
chemical compound
|
gptkbp:analyzes
|
in progress
|
gptkbp:application
|
used in drug formulation
|
gptkbp:campusFacilities
|
gptkb:XYZ_University
|
gptkbp:chemicalFormula
|
C12H16N2O2
amide
|
gptkbp:clinicalTrials
|
gptkb:USA
Phase II
promising
|
gptkbp:collaborations
|
gptkb:ABC_Pharmaceuticals
international
|
gptkbp:community_service
|
overall survival
not identified
|
gptkbp:compatibleWith
|
high
|
gptkbp:competitors
|
high
WPC-1109
|
gptkbp:composedOf
|
via acylation reaction
|
gptkbp:contraindication
|
headache
|
gptkbp:dissolved
|
soluble in water
|
gptkbp:dosageForm
|
once daily
|
gptkbp:drugInterdiction
|
studied
none known
under investigation
IND123456
|
gptkbp:endOfLife
|
4 hours
|
gptkbp:enrollment
|
ongoing
adults
|
gptkbp:environmentalImpact
|
low toxicity
|
gptkbp:exemplifies
|
lactose
|
gptkbp:fauna
|
mouse
|
gptkbp:formulation
|
tablet
|
gptkbp:funding
|
government grant
|
gptkbp:future_plans
|
clinical trials
|
https://www.w3.org/2000/01/rdf-schema#label
|
WPC-1108
|
gptkbp:iceClass
|
300 °C
150 °C
|
gptkbp:impact
|
nausea
favorable
|
gptkbp:ingredients
|
gptkb:WPC-1108
|
gptkbp:is_aimed_at
|
cancer
|
gptkbp:isATypeOf
|
123456-78-9
|
gptkbp:market
|
not yet approved
|
gptkbp:nutritionalValue
|
liver
|
gptkbp:origin
|
N-(4-(dimethylamino)phenyl)-2-hydroxy-2-(4-methylphenyl)acetamide
|
gptkbp:patentCitation
|
US1234567A
|
gptkbp:patentExpiration
|
2030
|
gptkbp:publications
|
Journal of Medicinal Chemistry
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
under review
|
gptkbp:related_to
|
WPC-1107
|
gptkbp:releaseYear
|
2010
|
gptkbp:research
|
NIH grant
|
gptkbp:research_areas
|
oncology
medicinal chemistry
|
gptkbp:route
|
oral
|
gptkbp:safety
|
handle with care
|
gptkbp:safety_features
|
acceptable
|
gptkbp:sponsor
|
gptkb:XYZ_Pharmaceuticals
|
gptkbp:storage
|
store in a cool, dry place
|
gptkbp:triggerType
|
inhibits cell proliferation
|
gptkbp:uses
|
pharmaceutical applications
|
gptkbp:waterManagement
|
urine
|
gptkbp:weight
|
220.27 g/mol
|